Washington D.C., Feb. 18, 2025- The Global Alzheimer’s Platform Foundation ® (GAP) is gravely concerned over news of terminations of key leaders at the National Institute of Health and the Federal Drug Administration along with the firing of thousands of employees from the Department of Health and Human Services over the weekend.
John Dwyer, the President of GAP stated: “We are outraged to learn of the thousands of federal workers who have been dismissed in a reckless decision that will have harmful consequences for people and families nationwide. This news is devastating, and possibly life-threatening, to the countless Americans who rely on critical health information and who benefit from research and drug discovery funds. It is especially alarming to learn that these decisions will result in cutting the pipeline for clinical trials, eliminating the promise of improved health and hope for millions of our friends, family and neighbors living with diseases that benefit from research, like cancer, heart disease and Alzheimer’s and related dementia.
Research is necessary for advancing science and saving lives. With a mission specific to finding cures for neurodegenerative diseases, we know that the only hope for patients facing a devastating diagnosis is the promise of future discoveries through clinical research. We strongly urge the administration to pause and reconsider the consequences that broad, sweeping cuts to the Department of Health and Human Services, National Institute of Health and Federal Drug Administration will undoubtedly have on all Americans.”
For immediate release:
Contact: media@globalalzplatform.org
About the Global Alzheimer’s Platform Foundation (GAP):
The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD and Parkinson’s disease clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.